![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Departments of Clinical Cancer Prevention and Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030
2To whom correspondence should be addressed.
With the inclusion of brief discussions of retinoid drug development in animal carcinogenesis models (e.g., skin, breast, oral cavity, lung, prostate or bladder) and clinical trials (e.g., head and neck or cervix), this review will focus on recent advances in retinoid molecular targeting studies designed primarily to develop retinoids with reduced toxicity, while maintaining or enhancing activity in the context of chemoprevention. Major current retinoid molecular targets include the six known nuclear retinoid receptors (RAR and RXR). Receptor numbers, distinct functions, tissue-expression patterns, ligand specificities, functional redundancy and regulation of multiple pathways make retinoid signaling highly complex. Development of receptor-selective synthetic retinoids is a major focus of molecular retinoid development. RAR heterodimerize with RXR and mediate classic retinoid activity/toxicity. RXR are more promiscuous, heterodimerizing with several other members of the steroid receptor superfamily [e.g., peroxisome proliferator-activated receptors (PPAR) or vitamin D receptors]. RXR-selective ligands are less toxic and more active in animal breast cancer prevention studies and less toxic than RAR ligands in clinical trials. Other new avenues of retinoid molecular drug development include newly identified retinoid-regulated genes, orphan-receptor ligands/functions, novel retinoid mechanisms involving potent receptor-independent apoptosis-inducing activity (e.g., 4-HPR or anhydroretinol), synergistic combinations [e.g., RXR agonists plus selective estrogen receptor modulators (SERM)], activity in other diseases and novel delivery systems.
KEY WORDS: • retinoids • chemoprevention • molecular targeting
This article has been cited by other articles:
|
|
 |
|
  L. R. Howe Rexinoids and Breast Cancer Prevention Clin. Cancer Res., October 15, 2007; 13(20): 5983 - 5987. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Safi, A. Kovacic, S. Gaillard, Y. Murata, E. R. Simpson, D. P. McDonnell, and C. D. Clyne Coactivation of Liver Receptor Homologue-1 by Peroxisome Proliferator-Activated Receptor {gamma} Coactivator-1{alpha} on Aromatase Promoter II and Its Inhibition by Activated Retinoid X Receptor Suggest a Novel Target for Breast-Specific Antiestrogen Therapy Cancer Res., December 15, 2005; 65(24): 11762 - 11770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ferrari, U. Pfeffer, R. Dell'Eva, C. Ambrosini, D. M. Noonan, and A. Albini The Transforming Growth Factor-{beta} Family Members Bone Morphogenetic Protein-2 and Macrophage Inhibitory Cytokine-1 as Mediators of the Antiangiogenic Activity of N-(4-Hydroxyphenyl)Retinamide Clin. Cancer Res., June 15, 2005; 11(12): 4610 - 4619. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Siegel, N. E. Craft, D. J. Roe, E. Duarte-Franco, L. L. Villa, E. L. Franco, and A. R. Giuliano Temporal Variation and Identification of Factors Associated with Endogenous Retinoic Acid Isomers in Serum from Brazilian Women Cancer Epidemiol. Biomarkers Prev., November 1, 2004; 13(11): 1693 - 1703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Subbarayan, A. L. Sabichi, J. Kim, N. Llansa, C. J. Logothetis, S. M. Lippman, and D. G. Menter Differential Peroxisome Proliferator-Activated Receptor-{gamma} Isoform Expression and Agonist Effects in Normal and Malignant Prostate Cells Cancer Epidemiol. Biomarkers Prev., November 1, 2004; 13(11): 1710 - 1716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Seguin-Devaux, Y. Devaux, V. Latger-Cannard, S. Grosjean, C. Rochette-Egly, F. Zannad, C. Meistelman, P.-M. Mertes, and D. Longrois Enhancement of the inducible NO synthase activation by retinoic acid is mimicked by RARalpha agonist in vivo Am J Physiol Endocrinol Metab, September 1, 2002; 283(3): E525 - E535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Benoit, M. Flexor, F. Besancon, L. Altucci, A. Rossin, J. Hillion, Z. Balajthy, L. Legres, E. Segal-Bendirdjian, H. Gronemeyer, et al. Autonomous Rexinoid Death Signaling Is Suppressed by Converging Signaling Pathways in Immature Leukemia Cells Mol. Endocrinol., July 1, 2001; 15(7): 1154 - 1169. [Abstract] [Full Text] [PDF]
|
|
